TRILEPTAL

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, South Africa, Spain, Turkey, UK.

Active ingredients

The drug TRILEPTAL contains one active pharmaceutical ingredient (API):

1	Oxcarbazepine UNII VZI5B1W380 - OXCARBAZEPINE
	The pharmacological activity of oxcarbazepine is primarily exerted through the metabolite (MHD). The mechanism of action of oxcarbazepine and MHD is thought to be mainly based on the blockade of voltage-sensitive sodium channels.
	Read more about Oxcarbazepine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRILEPTAL Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AF02	Oxcarbazepine	N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AF Carboxamide derivatives
Discover more medicines within N03AF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8584T, 8585W, 8586X, 8588B
BR	Câmara de Regulação do Mercado de Medicamentos	526515403119316, 526515404115314, 526515405111312, 526515408110317, 526515409117315, 526515410131415
CA	Health Products and Food Branch	02242068, 02242069, 02244673
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	27.199-08-06, 27.284-10-06, 367430813
EE	Ravimiamet	1009662, 1009673, 1009684, 1077230, 1077263, 1077274
ES	Centro de información online de medicamentos de la AEMPS	63093, 63095, 64398
FI	Lääkealan turvallisuus- ja kehittämiskeskus	422178, 552901, 556936, 556951
FR	Base de données publique des médicaments	61556061, 64876757, 66064587, 69568788
GB	Medicines & Healthcare Products Regulatory Agency	140118, 146852, 146854, 146856, 162799, 162801, 186172, 36728, 369022, 369024, 374086, 37842, 381715, 38401, 394092, 73155
HK	Department of Health Drug Office	49918, 50007, 50215
HR	Agencija za lijekove i medicinske proizvode	HR-H-007294503, HR-H-061545230, HR-H-309957904
IE	Health Products Regulatory Authority	29236, 37405, 44625, 49812, 49833, 49886, 74950, 74951
LT	Valstybinė vaistų kontrolės tarnyba	1002221, 1002223, 1014734
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	236M90, 362M94
NL	Z-Index G-Standaard	14896214
NL	Z-Index G-Standaard, PRK	56863, 56871, 70483
NZ	Medicines and Medical Devices Safety Authority	8716, 8718, 8719, 9885
PL	Rejestru Produktów Leczniczych	100096439, 100096445, 100189744, 100232196, 100350122, 100355680, 100357822, 100375926, 100376009
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W51416001, W51416002, W51416003, W51416004, W51416005, W51417001, W51417002, W51417003, W51417004, W51417005
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504090550, 8699504090604, 8699504700008
US	FDA, National Drug Code	0078-0337, 0078-0357, 0078-0456, 0078-0457, 55289-007
ZA	Health Products Regulatory Authority	34/2.5/0442, 36/2.5/0409, X/2.5/205, X/2.5/206